Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension.

Trial Profile

Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Amlodipine; Hydrochlorothiazide; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms OLMETREAT
  • Sponsors Daiichi Pharmaceutical; Sankyo
  • Most Recent Events

    • 09 Nov 2010 Additional trial identifier EudraCT2005-004659-36 identified as reported by ClinicalTrials.gov.
    • 02 May 2008 The expected completion date for this trial is now 1 Apr 2008.
    • 28 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top